Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of time-course forskolin (FSK) treatment versus rosiglitazone (Rosi) treatment on the chromatin accessibility landscape in a new immortalized mouse adipocyte progenitor (MAP) cell line (ATAC-Seq).

ABSTRACT: Effect of time-course forskolin (FSK) treatment versus rosiglitazone (Rosi) treatment on the chromatin accessibility landscape in a new immortalized mouse adipocyte progenitor (MAP) cell line (ATAC-Seq).

PROVIDER: PRJNA886073 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21776510_1.fastq.gz	Fastqsanger.gz
	SRR21776510_2.fastq.gz	Fastqsanger.gz
	SRR21776511_1.fastq.gz	Fastqsanger.gz
	SRR21776511_2.fastq.gz	Fastqsanger.gz
	SRR21776512_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

Effect of time-course forskolin (FSK) treatment versus rosiglitazone (Rosi) treatment on gene expression in a new immortalized mouse adipocyte progenitor (MAP) cell line (RNA-Seq).

Project description:Effect of time-course forskolin (FSK) treatment versus rosiglitazone (Rosi) treatment on gene expression in a new immortalized mouse adipocyte progenitor (MAP) cell line (RNA-Seq).

| PRJNA886072 | ENA

Effect of time-course forskolin (FSK) treatment versus rosiglitazone (Rosi) treatment on the chromatin accessibility landscape in a new immortalized mouse adipocyte progenitor (MAP) cell line

Project description:Effect of time-course forskolin (FSK) treatment versus rosiglitazone (Rosi) treatment on the chromatin accessibility landscape in a new immortalized mouse adipocyte progenitor (MAP) cell line

| PRJNA886071 | ENA

Effect of time-course forskolin (FSK) treatment versus rosiglitazone (Rosi) treatment on gene expression in a new immortalized mouse adipocyte progenitor (MAP) cell line (RNA-Seq).

Project description:To characterize biphasic adipocyte browning induced by chronic FSK treatment and compare this process to Rosi-induced browning, We performed gene expression profiling using MAP cells treated with vehicle or with FSK for mulitple time durations (4h, 1D, and 3D) or with Rosi for 3D.

2022-10-08 | GSE214596 | GEO

Effect of time-course forskolin (FSK) treatment versus rosiglitazone (Rosi) treatment on the chromatin accessibility landscape in a new immortalized mouse adipocyte progenitor (MAP) cell line (ATAC-Seq).

Project description:To investigate how the chromatin accessibility landscape is altered during biphasic FSK-induced browning in comparison with single-phase Rosi-induced browning, We performed chromatin lanscape profiling using the nuclei sorted from MAP cells treated with vehicle (Control) or with FSK for mulitple time durations (4 hours, 1 day, or 3 days) or with Rosi for 3 days.

2022-10-08 | GSE214597 | GEO

Expression data of mouse NIH3T3 and NIH3T3-k-ras transformed cell lines after Forskolin treatment

Project description:Forskolin treatment induces activation of protein kinase A. This activation protects transformed cells from death induced by glucose starvation. We used microarray to identify the mechanisms involved in such a pro-survival effect. NIH3T3 and NIH3T3-K-ras were plated at 1mM glucose and then daily treated or not with 10uM FSK until 72h of growth. The microarray analysis has been performed at 72h in order to identify specific mechanisms associate with transformed cells survival.

2015-10-24 | E-GEOD-68266 | biostudies-arrayexpress

scRNAseq analysis of forskolin effect on Th1, Th2 and Th17 differentiation

Project description:Adenylate cyclase signaling pathway is suggested to be a key regulator of immune system functions. However, specific effects of cyclic adenosine monophosphate on T helper cell differentiation and functions are unclear. Involvement of cAMP in Th cell differentiation program, in particular development of Th1, Th2, and Th17 subsets, was evaluated employing forskolin (FSK), a labdane diterpene well known as AC activator.

2022-12-14 | GSE220589 | GEO

Transcriptomic Profiling of the Telomerase Transformed Mesenchymal Stromal Cells Derived Adipocytes in Response to Rosiglitazone.

Project description:In our earlier study, it was shown that Rosiglitazone enhances the brown adipogenesis of Immortalized Human Bone Marrow Mesenchymal Stromal Cells - hTERT (iMSC3). The current study compared the transcriptomics profiles of the different adipocytes derived from iMSC3 reported in our previous study. The complete transcriptomic profiles of iMSCs and adipocytes differentiated with and without Rosiglitazone treatment revealed a set of marker genes that warrant further investigation. The transcriptomics analysis revealed the upregulation and uniquely expression of genes due to Rosiglitazone treatment seems to have roles in brown adipogenesis.

2022-03-30 | GSE171826 | GEO

SF-1 and RNF31 knockdown and forskolin treatment

Project description:The human adrenocortical carcinoma cell line NCI-H295R treated with siRNA targeting SF-1 or RNF31 with luciferase-targeting siRNA as control. Combined with forskolin treatment.

2012-02-01 | E-MEXP-3259 | biostudies-arrayexpress

Differentiation of human monocytes to macrophages in the presence of GM-CSF +/- forskolin (FSK)

Project description:Macrophages are central mediators of the innate immune system that can be differentiated from monocytes upon exposure to cytokines. While increased cyclic adenosine monophosphate (cAMP) levels inhibit many lipopolysaccharide (LPS) -elicited macrophage inflammatory responses, the effects of elevated cAMP on macrophage differentiation are not well understood. We have differentiated monocytes to macrophages in the presence of GM-CSF or GM-CSF + FSK to elevate cAMP levels and determine its effects on differentiation. Microarray analysis was performed separately on samples from 3 human donors: 3 control and 3 forskolin-treated samples.

2010-06-20 | E-GEOD-18654 | biostudies-arrayexpress

Pioglitazone, rosiglitazone and troglitazone treatment

Project description:3T3-L1 cells treated 24 hours with either 0.1% DMSO, 20uM pioglitazone, 1uM rosiglitazone or 20uM troglitazone Keywords: other

2004-08-01 | GSE1458 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data